BeOne Medicines Net Debt Growth & History (ONC)
BeOne Medicines's net debt was −$3.45B for fiscal 2025.
View full BeOne Medicines company overviewBeOne Medicines annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$3.45B | −$2.75B | — |
| 2024 | 2024-12-31 | −$696.0M | $1.55B | — |
| 2023 | 2023-12-31 | −$2.24B | $1.03B | — |
| 2022 | 2022-12-31 | −$3.27B | $408.1M | — |
| 2021 | 2021-12-31 | −$3.68B | −$3.20B | — |
| 2020 | 2020-12-31 | −$485.0M | $13.1M | — |
| 2019 | 2019-12-31 | −$498.1M | $165.4M | — |
| 2018 | 2018-12-31 | −$663.4M | −$442.3M | — |
| 2017 | 2017-12-31 | −$221.2M | −$150.9M | — |
| 2016 | 2016-12-31 | −$70.2M | — | — |
BeOne Medicines quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$3.88B | −$2.15B | — |
| Q1 2026 | 2026-03-31 | −$3.63B | −$2.11B | — |
| Q4 2025 | 2025-12-31 | −$3.45B | −$2.75B | — |
| Q3 2025 | 2025-09-30 | −$3.16B | −$1.56B | — |
| Q2 2025 | 2025-06-30 | −$1.73B | −$227.7M | — |
| Q1 2025 | 2025-03-31 | −$1.52B | $210.7M | — |
| Q4 2024 | 2024-12-31 | −$696.0M | $1.55B | — |
| Q3 2024 | 2024-09-30 | −$1.60B | $887.1M | — |
| Q2 2024 | 2024-06-30 | −$1.50B | $1.23B | — |
| Q1 2024 | 2024-03-31 | −$1.73B | $1.26B | — |
| Q4 2023 | 2023-12-31 | −$2.24B | $1.03B | — |
| Q3 2023 | 2023-09-30 | −$2.49B | $999.0M | — |
| Q2 2023 | 2023-06-30 | −$2.73B | $1.17B | — |
| Q1 2023 | 2023-03-31 | −$2.99B | $681.8M | — |
| Q4 2022 | 2022-12-31 | −$3.27B | $408.1M | — |
| Q3 2022 | 2022-09-30 | −$3.49B | −$2.80B | — |
| Q2 2022 | 2022-06-30 | −$3.90B | −$2.80B | — |
| Q1 2022 | 2022-03-31 | −$3.68B | −$2.41B | — |
| Q4 2021 | 2021-12-31 | −$3.68B | −$3.20B | — |
| Q3 2021 | 2021-09-30 | −$683.8M | $537.0M | — |
| Q2 2021 | 2021-06-30 | −$1.10B | $47.3M | — |
| Q1 2021 | 2021-03-31 | −$1.26B | $553.1M | — |
| Q4 2020 | 2020-12-31 | −$485.0M | $13.1M | — |
| Q3 2020 | 2020-09-30 | −$1.22B | −$498.3M | — |
| Q2 2020 | 2020-06-30 | −$1.14B | −$345.5M | — |
| Q1 2020 | 2020-03-31 | −$1.82B | −$1.17B | — |
| Q4 2019 | 2019-12-31 | −$498.1M | $165.4M | — |
| Q3 2019 | 2019-09-30 | −$722.4M | −$128.5M | — |
| Q2 2019 | 2019-06-30 | −$797.9M | −$420.0M | — |
| Q1 2019 | 2019-03-31 | −$649.1M | −$177.6M | — |
| Q4 2018 | 2018-12-31 | −$663.4M | −$442.3M | — |
| Q3 2018 | 2018-09-30 | −$593.9M | −$394.4M | — |
| Q2 2018 | 2018-06-30 | −$377.9M | — | — |
| Q1 2018 | 2018-03-31 | −$471.5M | −$376.2M | — |
| Q4 2017 | 2017-12-31 | −$221.2M | −$150.9M | — |
| Q3 2017 | 2017-09-30 | −$199.5M | — | — |
| Q1 2017 | 2017-03-31 | −$95.3M | — | — |
| Q4 2016 | 2016-12-31 | −$70.2M | — | — |
BeOne Medicines net debt trends
Over the last five fiscal years, BeOne Medicines's net debt decreased from −$485.0M to −$3.45B, a change of −$2.96B. The latest reported quarter, Q2 2026, shows −$3.88B.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BeOne Medicines source filings ↗